Market Closed -
Nasdaq
01:30:00 09/05/2024 am IST
|
5-day change
|
1st Jan Change
|
9.6
USD
|
-0.10%
|
|
+8.72%
|
+4.35%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,240
|
578.9
|
264.8
|
501.9
|
647.9
|
-
|
-
|
Enterprise Value (EV)
1 |
1,240
|
578.9
|
264.8
|
266.8
|
647.9
|
647.9
|
647.9
|
P/E ratio
|
-10.1
x
|
-7.1
x
|
-2.62
x
|
-4.69
x
|
-5.57
x
|
-4.99
x
|
-4.72
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
27.5
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
27.5
x
|
EV / EBITDA
|
-16.9
x
|
-7.42
x
|
-2.92
x
|
-4.57
x
|
-5.44
x
|
-5.11
x
|
-5.98
x
|
EV / FCF
|
-27
x
|
-9.57
x
|
-3.43
x
|
-5.8
x
|
-8.31
x
|
-6
x
|
-4.35
x
|
FCF Yield
|
-3.7%
|
-10.4%
|
-29.2%
|
-17.2%
|
-12%
|
-16.7%
|
-23%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
36,634
|
39,382
|
44,953
|
54,552
|
67,422
|
-
|
-
|
Reference price
2 |
33.85
|
14.70
|
5.890
|
9.200
|
9.610
|
9.610
|
9.610
|
Announcement Date
|
23/03/21
|
21/03/22
|
16/03/23
|
11/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
23.55
|
EBITDA
1 |
-
|
-73.22
|
-77.97
|
-90.8
|
-109.7
|
-119
|
-126.8
|
-108.4
|
EBIT
1 |
-28.57
|
-74.19
|
-78.87
|
-91.77
|
-110.8
|
-124.9
|
-146.6
|
-163.9
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-696.19%
|
Earnings before Tax (EBT)
1 |
-
|
-73.7
|
-78.72
|
-89.12
|
-100.7
|
-113.9
|
-139.8
|
-155.8
|
Net income
1 |
-
|
-73.7
|
-78.72
|
-89.12
|
-100.7
|
-113.8
|
-139.1
|
-155.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-661.73%
|
EPS
2 |
-
|
-3.360
|
-2.070
|
-2.250
|
-1.960
|
-1.724
|
-1.926
|
-2.036
|
Free Cash Flow
1 |
-
|
-45.94
|
-60.48
|
-77.22
|
-86.54
|
-78
|
-108
|
-149
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-632.81%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/20
|
23/03/21
|
21/03/22
|
16/03/23
|
11/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-21.87
|
-25.42
|
-24.73
|
-28.42
|
-31.16
|
-28.73
|
-29.51
|
-30.09
|
-30.69
|
-
|
-
|
EBIT
1 |
-22.8
|
-23.26
|
-20.7
|
-25.69
|
-22.12
|
-25.68
|
-24.99
|
-28.68
|
-31.43
|
-28.99
|
-30.55
|
-31.99
|
-33.23
|
-33.66
|
-34.48
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.77
|
-23.16
|
-20.29
|
-24.83
|
-20.85
|
-23.94
|
-22.94
|
-25.48
|
-28.33
|
-25.01
|
-27.72
|
-29.67
|
-31.39
|
-32.8
|
-33.5
|
Net income
1 |
-22.77
|
-23.16
|
-20.29
|
-24.83
|
-20.85
|
-23.94
|
-22.94
|
-25.48
|
-28.33
|
-25.01
|
-27.81
|
-29.64
|
-31.26
|
-32.22
|
-33.18
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5800
|
-0.5900
|
-0.5100
|
-0.6300
|
-0.5200
|
-0.5300
|
-0.5000
|
-0.4400
|
-0.4900
|
-0.3700
|
-0.4122
|
-0.4347
|
-0.4572
|
-0.4800
|
-0.4933
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/03/22
|
09/05/22
|
11/08/22
|
07/11/22
|
16/03/23
|
08/05/23
|
10/08/23
|
06/11/23
|
11/03/24
|
06/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
235
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-45.9
|
-60.5
|
-77.2
|
-86.5
|
-78
|
-108
|
-149
|
ROE (net income / shareholders' equity)
|
-39%
|
-28%
|
-36%
|
-45.1%
|
-50%
|
-44.7%
|
-34.2%
|
ROA (Net income/ Total Assets)
|
-37.5%
|
-26.3%
|
-32.7%
|
-40.3%
|
-44.9%
|
-40.2%
|
-
|
Assets
1 |
196.5
|
298.8
|
272.9
|
249.6
|
253.8
|
346
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.67
|
0.94
|
2.08
|
0.85
|
-
|
0.5
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
4.25%
|
Announcement Date
|
23/03/21
|
21/03/22
|
16/03/23
|
11/03/24
|
-
|
-
|
-
|
Last Close Price
9.61
USD Average target price
18.88
USD Spread / Average Target +96.41% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.35% | 648M | | +2.93% | 106B | | +7.02% | 23.47B | | -14.60% | 21.9B | | -7.05% | 18.77B | | -38.55% | 17.85B | | -8.83% | 16.78B | | +5.51% | 14.41B | | +37.49% | 12.86B | | +329.39% | 8.78B |
Bio Therapeutic Drugs
|